A Phase II Study of Lenalidomide Alone in Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes With Chromosome 5 Abnormalities

This phase II study assessed the efficacy and safety of lenalidomide in patients with relapsed/refractory acute myeloid leukemia (N = 18) and high-risk myelodysplastic syndrome (N = 9) with chromosome 5 abnormalities. The overall complete remission rate with or without platelet recovery was 7% (2/27...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Chen, Yiming, Kantarjian, Hagop, Estrov, Zeev, Faderl, Stefan, Ravandi, Farhad, Rey, Kristy, Cortes, Jorge, Borthakur, Gautam
Médium: Artigo
Jazyk:Inglês
Vydáno: 2012
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4103411/
https://ncbi.nlm.nih.gov/pubmed/22579233
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clml.2012.04.001
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky